NUVISAN



LIFE SCIENCE CHEMISTRY

Targeted Protein Degradation Platform

www.nuvisan.com

TARGETED PROTEIN DEGRADATION PLATFORM

PROTACs LIBRARY WITH

>20 Ligands for E3 ligases
>7k Linkers
>100 Precursors

End to End Design

Smart design and Linkerology for PROTACs and Molecular glues supported by AI

34 SCIENTISTS

> 94% with PhD



83 LAB PROFESSIONALS

EFFICIENT SYNTHESIS & DIRECT-TO-BIOLOGY

100+ degraders per day



> 300

FUME HOODS IN THE CHEMISTRY LAB

CUSTOMIZED PROTACS FROM MG TO KG GMP & NON-GMP

NUVISAN

Our Targeted Protein Degradation Platform

With decades of expertise in drug discovery combined with our cutting-edge degradation platform, we provide innovative strategies for rapid discovery of PROTACs and molecular glues across all business models including consulting, degrader library synthesis and integrated projects from conception to success.

- **Flexible starting point:** Optimization of client`s already existing POI- and/or E3 ligase-binders or the discovery of entirely new POI- and/or E3 ligase-binders. World class protein sciences and biophysics teams to unlock even the most difficult targets
- Various end point: With our **smart design** and **multi-parameter optimization strategy**, we provide the clients with advanced compounds to reach any milestone in the preclinical pipeline and with high quality data packages
- Tailor-made solution: With **focused library design, state-of-the-art synthesis methods** and **direct-to biology approaches**, we offer the most suitable solution for your projects with significantly reduced cycle time
- **Client-centered and goal-oriented team:** We are expert drug hunters with a collaborative mindset and problem-solving enthusiasts. We share your sense of urgency to deliver high quality compounds/candidates



Targeted Protein Degradation Platform for your Drug Discovery Program

PROTACs and Glues Smart Design

Innovative design platform combined with prediction tools and historical data streamline the prioritization of compounds for synthesis.

- Data Mining
- Warhead Design: Scaffold hopping, pharmacophore-based docking
- *De Novo* linker design (LINK-invent) and structure-based linker optimization
- Prediction tool (e.g., for ternary complex prediction, solubility, permeability)
- End-to-End degrader design

Building Blocks and Linkers

Ready-to-use collection of linkers and E3 binders increases the efficiency of synthesis of degraders.

- Structurally highly diverse set of linkers and E3 binders
- Current library consists of > 20 Ligands for E3 ligases, > 7k linkers and > 100 precursors ready to conjugate with POI binder
- Continuously growing

NUVISAN

Multi-Parameter Optimization

Data generation and data analysis using modern visualization tools result in data-driven design and prioritization of compounds.

- Optimize PK-PD parameters and safety properties by smart design and linkerology to provide candidates appropriate for the designated routes of administration
- Smart design and linkerology
- A robust screening tree, combined with reduced cycle times enable rapid generation of data to support further design

Efficient Synthesis & Direct-to-Biology

State of the art parallel synthesis and assay technology ensure a direct-to-biology approach to accelerate the project significantly.

- Parallel synthesis with and without solid phase supported synthesis
- Plate based chemistry and pool synthesis: Compounds can be tested without prior purification
- 100+ degraders per day by parallel synthesis, pool synthesis and plate base chemistry
- Direct-to-Biology assays: SPR, ASMS, HiBiT and others

Purification & Analytical Services

In-house purification and analytics services to support your project or as standalone service.

- Specialized NMR measurements (up to 600 MHz NMR with cryo-probe)
- Structure elucidation by experts and certificates of analysis
- Dedicated high-throughput purification lab from mg to g scales and chiral separation expertise (e.g. SFC, chiral phases)
- Determination of PhysChem parameters (e.g. EPSA, ChromLogD 7.4, solubility, lipophilicity, stability, crystallinity)

NUVISAN

The Science CRO - From Target to Patient

The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with six sites in Germany and France as well as local experts situated in Latin America.

We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient.

Thanks to more than 40 years of experience and about 1,000 employees (incl. > 70 % industry experienced scientists and lab professionals), we know how to discover, develop, and bring the next generation medicines to market. At the same time, our scientists understand that every project is different. With a flexible and innovative approach and transparent communication, our teams are passionate about closely collaborating with you to adapt to your individual needs.



Contact us

Dr. Duy Nguyen
Principal Scientist
duy.nguyen@nuvisan.com

Dr. Christoph Sachse
VP Business Development
christoph.sachse@nuvisan.com

NUVISAN ICB GmbH
Muellerstr. 178
13353 Berlin, Germany

Web: www.nuvisan.com
Email: hello@nuvisan.com
LinkedIn: company/nuvisan

PROTACs I 11-2023 I Wmd